Roche (OTCMKTS:RHHBY) Rating Increased to Strong-Buy at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Roche (OTCMKTS:RHHBY) to a strong-buy rating in a report issued on Thursday,Zacks.com reports.

Roche Stock Down 1.5 %

RHHBY opened at $39.25 on Thursday. Roche has a 12-month low of $29.20 and a 12-month high of $42.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97. The firm has a 50 day moving average of $36.14 and a two-hundred day moving average of $38.25.

Hedge Funds Weigh In On Roche

Several institutional investors have recently made changes to their positions in RHHBY. Bard Financial Services Inc. grew its stake in Roche by 112.1% in the 3rd quarter. Bard Financial Services Inc. now owns 66,500 shares of the company’s stock valued at $2,657,000 after acquiring an additional 35,150 shares during the period. GAMMA Investing LLC boosted its stake in Roche by 57.7% during the 3rd quarter. GAMMA Investing LLC now owns 7,944 shares of the company’s stock worth $317,000 after purchasing an additional 2,906 shares during the last quarter. Diversified Trust Co boosted its stake in Roche by 6.4% during the 3rd quarter. Diversified Trust Co now owns 59,742 shares of the company’s stock worth $2,396,000 after purchasing an additional 3,613 shares during the last quarter. AlphaMark Advisors LLC acquired a new stake in Roche during the 3rd quarter worth $149,000. Finally, Kornitzer Capital Management Inc. KS boosted its stake in Roche by 1.3% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock worth $5,490,000 after purchasing an additional 1,798 shares during the last quarter.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.